10x Genomics (TXG) 10-Q 4 May 23 2023 Q1 Quarterly report Financial data

Cover Page

Cover Page - shares	3 Months Ended
	Mar. 31, 2023	Apr. 28, 2023
Entity Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2023
Document Transition Report	false
Entity File Number	001-39035
Entity Registrant Name	10x Genomics, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	45-5614458
Entity Address, Address Line One	6230 Stoneridge Mall Road
Entity Address, City or Town	Pleasanton
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94588
City Area Code	925
Local Phone Number	401-7300
Title of 12(b) Security	Class A common stock, par value $0.00001 per share
Trading Symbol	TXG
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Amendment Flag	false
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q1
Current Fiscal Year End Date	--12-31
Entity Central Index Key	0001770787
Common Class A
Entity Information [Line Items]
Entity Common Stock, Shares Outstanding		98,124,868
Common Class B
Entity Information [Line Items]
Entity Common Stock, Shares Outstanding		18,067,255

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 332,320	$ 219,746
Marketable securities	85,970	210,238
Restricted cash	2,500	2,633
Accounts receivable, net	77,940	104,211
Inventory	82,307	81,629
Prepaid expenses and other current assets	20,857	16,578
Total current assets	601,894	635,035
Property and equipment, net	292,106	289,328
Restricted cash	4,974	4,974
Operating lease right-of-use assets	74,738	69,882
Goodwill	4,511	4,511
Intangible assets, net	22,948	22,858
Other noncurrent assets	12,859	2,392
Total assets	1,014,030	1,028,980
Current liabilities:
Accounts payable	29,317	21,599
Accrued compensation and related benefits	17,574	32,675
Accrued expenses and other current liabilities	47,386	59,779
Deferred revenue	8,530	7,867
Operating lease liabilities	9,199	9,037
Total current liabilities	112,006	130,957
Operating lease liabilities, noncurrent	92,843	86,139
Other noncurrent liabilities	6,796	6,141
Total liabilities	211,645	223,237
Commitments and contingencies (Note 4)
Stockholders’ equity:
Preferred stock	0	0
Common stock	2	2
Additional paid-in capital	1,883,930	1,839,397
Accumulated deficit	(1,080,068)	(1,029,321)
Accumulated other comprehensive loss	(1,479)	(4,335)
Total stockholders’ equity	802,385	805,743
Total liabilities and stockholders’ equity	$ 1,014,030	$ 1,028,980

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Income Statement [Abstract]
Revenue	$ 134,285	$ 114,496
Cost of revenue	35,895	25,478
Gross profit	98,390	89,018
Operating expenses:
Research and development	67,098	64,078
Selling, general and administrative	83,280	66,675
Total operating expenses	150,378	130,753
Loss from operations	(51,988)	(41,735)
Other income (expense):
Interest income	3,869	569
Interest expense	(19)	(128)
Other expense, net	(1,516)	(400)
Total other income	2,334	41
Loss before provision for income taxes	(49,654)	(41,694)
Provision for income taxes	1,093	719
Net loss	$ (50,747)	$ (42,413)
Net loss per share, basic (in dollars per share)	$ (0.44)	$ (0.38)
Net loss per share, diluted (in dollars per share)	$ (0.44)	$ (0.38)
Weighted-average shares of common stock used in computing net loss per share, basic (in shares)	115,619,869	112,966,196
Weighted-average shares of common stock used in computing net loss per share, diluted (in shares)	115,619,869	112,966,196

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Statement of Comprehensive Income [Abstract]
Net loss	$ (50,747)	$ (42,413)
Other comprehensive income (loss), net of tax:
Unrealized gains (losses) on available-for-sale marketable securities	1,117	(2,403)
Realized loss on available-for-sale marketable securities reclassified into net loss	1,715	0
Foreign currency translation adjustment	24	(62)
Other comprehensive income (loss), net of tax	2,856	(2,465)
Comprehensive loss	$ (47,891)	$ (44,878)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders’ Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Income (Loss)	Common Class A	Common Class A Common Stock	Common Class A Additional Paid-in Capital
Beginning balance (in shares) at Dec. 31, 2021		112,514,977
Beginning balance at Dec. 31, 2021	$ 817,568	$ 2	$ 1,680,865	$ (863,321)	$ 22
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of Class A common stock related to equity awards (in shares)							761,373
Issuance of Class A common stock related to equity awards						$ 7,826		$ 7,826
Vesting of shares subject to repurchase, including early exercised options	32		32
Stock-based compensation	26,137		26,137
Net loss	(42,413)			(42,413)
Other comprehensive income (loss)	(2,465)				(2,465)
Ending balance (in shares) at Mar. 31, 2022		113,276,350
Ending balance at Mar. 31, 2022	806,685	$ 2	1,714,860	(905,734)	(2,443)
Beginning balance (in shares) at Dec. 31, 2022		115,195,009
Beginning balance at Dec. 31, 2022	805,743	$ 2	1,839,397	(1,029,321)	(4,335)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of Class A common stock related to equity awards (in shares)							978,333
Issuance of Class A common stock related to equity awards						$ 2,400		$ 2,400
Stock-based compensation	42,133		42,133
Net loss	(50,747)			(50,747)
Other comprehensive income (loss)	2,856				2,856
Ending balance (in shares) at Mar. 31, 2023		116,173,342
Ending balance at Mar. 31, 2023	$ 802,385	$ 2	$ 1,883,930	$ (1,080,068)	$ (1,479)

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Operating activities:
Net loss	$ (50,747)	$ (42,413)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	42,101	26,047
Depreciation and amortization	6,482	6,191
Amortization of right-of-use assets	2,134	1,784
Realized loss on marketable securities	1,715	0
Other	150	183
Changes in operating assets and liabilities:
Accounts receivable	26,279	8,728
Inventory	(449)	(3,736)
Prepaid expenses and other current assets	(4,253)	(3,873)
Other noncurrent assets	(10,470)	157
Accounts payable	(781)	2,875
Accrued compensation and other related benefits	(15,129)	(13,283)
Deferred revenue	1,051	230
Accrued expenses and other current liabilities	(161)	(3,541)
Operating lease liability	(2,308)	(357)
Other noncurrent liabilities	261	206
Net cash used in operating activities	(4,125)	(20,802)
Investing activities:
Purchases of property and equipment	(4,559)	(28,136)
Acquisition of intangible assets	(723)	0
Purchase of marketable securities	0	(242,329)
Proceeds from sales of marketable securities	93,342	12,657
Proceeds from maturities of marketable securities	31,896	250
Net cash provided by (used in) investing activities	119,956	(257,558)
Financing activities:
Payments on financing arrangement	(5,814)	(5,409)
Issuance of common stock from exercise of stock options	2,400	7,826
Net cash (used in) provided by financing activities	(3,414)	2,417
Effect of exchange rate changes on cash, cash equivalents, and restricted cash	24	(18)
Net increase (decrease) in cash, cash equivalents, and restricted cash	112,441	(275,961)
Cash, cash equivalents, and restricted cash at beginning of period	227,353	596,073
Cash, cash equivalents, and restricted cash at end of period	339,794	320,112
Supplemental disclosures of cash flow information:
Cash paid for interest	436	841
Cash paid for taxes	2,547	2,900
Noncash investing and financing activities:
Purchases of property and equipment included in accounts payable and accrued expenses and other current liabilities	30,668	15,023
Right-of-use assets obtained in exchange for new operating lease liabilities	6,893	16,562
Contingent consideration payable from business acquisition	$ 0	$ 1,500

Description of Business and Bas

Description of Business and Basis of Presentation	3 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business and Basis of Presentation	Description of Business and Basis of Presentation Organization and Description of Business 10x Genomics, Inc. (the “Company”) is a life sciences technology company focused on building innovative products and solutions to interrogate, understand and master biological systems at resolution and scale that matches the complexity of biology. The Company’s integrated solutions include the Company’s Chromium X Series and Chromium Connect instruments, which the Company refers to as “Chromium instruments,” the Company's Visium CytAssist and Xenium Analyzer instruments, which the Company refers to as “Spatial instruments,” and the Company’s proprietary microfluidic chips, slides, reagents and other consumables for the Company's Chromium, Visium and Xenium solutions, which the Company refers to as “consumables.” The Company bundles its software with these products to guide customers through the workflow, from sample preparation through analysis and visualization. The Company was incorporated in the state of Delaware in July 2012 and began commercial and manufacturing operations and selling its instruments and consumables in 2015. The Company is headquartered in Pleasanton, California and has wholly-owned subsidiaries in Asia, Europe and North America. Basis of Presentation The accompanying condensed consolidated financial statements, which include the Company’s accounts and the accounts of its wholly-owned subsidiaries, are unaudited and have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). The condensed consolidated balance sheets at December 31, 2022 have been derived from the audited consolidated financial statements of the Company at that date. Certain information and footnote disclosures typically included in the Company’s audited consolidated financial statements have been condensed or omitted. The accompanying unaudited condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to state fairly the Company’s financial position, results of operations, comprehensive loss and cash flows for the periods presented, but are not necessarily indicative of the results of operations to be anticipated for any future annual or interim period. All intercompany transactions and balances have been eliminated. The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities. Actual results could differ from those estimates. The inputs into our judgments and estimates consider the economic implications of COVID-19 on our critical and significant accounting estimates. The accompanying unaudited condensed consolidated financial statements and notes should be read in conjunction with the audited consolidated financial statements and related notes for the year ended December 31, 2022 included in the Company's Annual Report on Form 10-K filed with the SEC on February 16, 2023 (our "Annual Report").

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies There were no material changes in the Company's significant accounting policies during the three months ended March 31, 2023. See Note 2 – Summary of Significant Accounting Policies to the consolidated financial statements included in the Company's Annual Report, for information regarding the Company's significant accounting policies. Revenue Recognition The Company generates revenue from sales of products and services, and its products consist of instruments and consumables. Revenue from product sales is recognized when control of the product is transferred, which is generally upon shipment to the customer. Instrument service agreements, which relate to extended warranties, are typically entered into for one-year terms, following the expiration of the standard one-year warranty period. Revenue for extended warranties is recognized ratably over the term of the extended warranty period as a stand ready performance obligation. Revenue is recorded net of discounts, distributor commissions and sales taxes collected on behalf of governmental authorities. Customers are invoiced generally upon shipment, or upon order for services, and payment is typically due within 45 days. Cash received from customers in advance of product shipment or providing services is recorded as a contract liability. The Company’s contracts with its customers generally do not include rights of return or a significant financing component. The Company regularly enters into contracts that include various combinations of products and services which are generally distinct and accounted for as separate performance obligations. The transaction price is allocated to each performance obligation in proportion to its standalone selling price. The Company determines standalone selling price using average selling prices with consideration of current market conditions. If the product or service has no history of sales or if the sales volume is not sufficient, the Company relies upon prices set by management, adjusted for applicable discounts. Net Loss Per Share Net loss per share is computed using the two-class method required for multiple classes of common stock and participating securities. The rights, including the liquidation and dividend rights and sharing of losses, of the Class A common stock and Class B common stock are identical, other than voting rights. As the liquidation and dividend rights and sharing of losses are identical, the undistributed earnings are allocated on a proportionate basis and the resulting net loss per share will, therefore, be the same for both Class A and Class B common stock on an individual or combined basis. Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period, adjusted for outstanding shares that are subject to repurchase. For the calculation of diluted net loss per share, basic net loss per share is adjusted by the effect of dilutive securities including awards under the Company’s equity compensation plans. Diluted net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding. For periods in which the Company reports net losses, diluted net loss per share is the same as basic net loss per share because potentially dilutive shares of common stock are not assumed to have been issued if their effect is anti-dilutive.

Other Financial Statement Infor

Other Financial Statement Information	3 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Other Financial Statement Information	Other Financial Statement Information Available-for-sale Securities Available-for-sale securities consisted of the following (in thousands): March 31, 2023 December 31, 2022 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Fair Value Measurement Cash equivalents: Money market funds $ 302,826 $ — $ — $ 302,826 $ 163,184 $ — $ — $ 163,184 Level 1 Marketable securities: Corporate debt securities 32,623 — (382) 32,241 153,794 4 (2,768) 151,030 Level 2 Government debt securities 49,632 — (828) 48,804 54,136 — (1,247) 52,889 Level 2 Asset-backed securities 4,999 — (74) 4,925 6,424 — (105) 6,319 Level 2 Total available-for-sale securities $ 390,080 $ — $ (1,284) $ 388,796 $ 377,538 $ 4 $ (4,120) $ 373,422 The contractual maturities of marketable securities as of March 31, 2023 were as follows (in thousands): Fair Value Due in one year or less $ 66,133 Due after one year to five years 19,837 Total marketable securities $ 85,970 During the three months ended March 31, 2023, the Company incurred gross realized losses of $1.7 million and no gross realized gains from the sale of available-for-sales debt securities. The Company incurred no material gross realized gains or losses from available-for-sales debt securities during the three months ended March 31, 2022. Realized gains (losses) on the sale of marketable securities are recorded in “Other expense, net” in the condensed consolidated statements of operations. The available-for-sale debt securities are subject to a periodic impairment review. For investments in an unrealized loss position, the Company determines whether a credit loss exists by considering information about the collectability of the instrument, current market conditions and reasonable and supportable forecasts of economic conditions. The Company recognizes an allowance for credit losses, up to the amount of the unrealized loss when appropriate, and writes down the amortized cost basis of the investment if it is more likely than not that the Company will be required or will intend to sell the investment before recovery of its amortized cost basis. Allowances for credit losses and write-downs are recognized in “Other (expense) income, net,” and unrealized losses not related to credit losses are recognized in “Accumulated other comprehensive income (loss).” There are no allowances for credit losses for the periods presented. As of March 31, 2023, the gross unrealized losses on available-for-sale securities are related to market interest rate changes and not attributable to credit. Inventory Inventory was comprised of the following (in thousands): March 31, December 31, Purchased materials $ 37,100 $ 34,497 Work in progress 20,530 24,650 Finished goods 24,677 22,482 Inventory $ 82,307 $ 81,629 Accrued Compensation and Related Benefits Accrued compensation and related benefits were comprised of the following as of the dates indicated (in thousands): March 31, December 31, Accrued payroll and related costs $ 4,298 $ 2,052 Accrued bonus 5,587 17,081 Accrued commissions 2,769 5,143 Accrued acquisition-related compensation — 5,470 Other 4,920 2,929 Accrued compensation and related benefits $ 17,574 $ 32,675 Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities were comprised of the following as of the dates indicated (in thousands): March 31, December 31, Accrued legal and related costs $ 5,639 $ 3,102 Accrued license fee — 6,231 Accrued royalties for licensed technologies 4,501 4,707 Accrued property and equipment 22,167 26,750 Accrued professional services 4,318 5,180 Product warranties 3,206 3,023 Taxes payable 2,297 4,079 Other 5,258 6,707 Accrued expenses and other current liabilities $ 47,386 $ 59,779 Product Warranties Changes in the reserve for product warranties were as follows for the periods indicated (in thousands): Three Months Ended 2023 2021 Beginning of period $ 3,023 $ 994 Amounts charged to cost of revenue 1,630 775 Repairs and replacements (1,447) (672) End of period $ 3,206 $ 1,097 Revenue and Deferred Revenue As of March 31, 2023, the aggregate amount of remaining performance obligations related to separately sold extended warranty service agreements, or allocated amounts for extended warranty service agreements bundled with sales of instruments, was $12.1 million, of which approximately $8.5 million is expected to be recognized to revenue in the next 12 months, with the remainder thereafter. The contract liabilities of $12.1 million and $11.0 million as of March 31, 2023 and December 31, 2022, respectively, consisted of deferred revenue related to extended warranty service agreements. The following revenue recognized for the periods were included in contract liabilities as of December 31, 2022 and December 31, 2021 (in thousands): Three Months Ended 2023 2022 Deferred revenue recognized $ 2,107 $ 1,604 The following table represents revenue by source for the periods indicated (in thousands). Spatial products include the Company's Visium and Xenium products: Three Months Ended 2023 2022 Instruments Chromium $ 11,626 $ 14,326 Spatial¹ 7,550 103 Total instruments revenue 19,176 14,429 Consumables Chromium 101,096 91,279 Spatial 11,282 6,671 Total consumables revenue 112,378 97,950 Services 2,731 2,117 Total revenue $ 134,285 $ 114,496 1 The Spatial instruments revenue in the first quarter of 2022 related to revenue from the Visium Accessory Kit. The following table presents revenue by geography based on the location of the customer for the periods indicated (in thousands): Three Months Ended 2023 2022 Americas United States $ 76,281 $ 57,441 Americas (excluding United States) 2,515 2,246 Total Americas 78,796 59,687 Europe, Middle East and Africa 28,422 20,532 Asia-Pacific China¹ 14,031 21,782 Asia-Pacific (excluding China) 13,036 12,495 Total Asia-Pacific 27,067 34,277 Total Revenue $ 134,285 $ 114,496 1

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Lease Agreements The Company leases office, laboratory, manufacturing and distribution space in various locations worldwide. On November 6, 2020, the Company entered into a Master Lease Agreement ("MLA"), consisting of various lease components, to lease additional office building space near the Company's Pleasanton, California headquarters. All of the lease components related to the MLA have commenced and the MLA is expected to terminate on June 30, 2033. Future net lease payments related to the Company’s operating lease liabilities as of March 31, 2023 is as follows (in thousands): Operating Leases 2023 (excluding the three months ended March 31, 2023) $ 10,208 2024 16,435 2025 15,330 2026 16,101 2027 15,476 Thereafter 56,475 Total lease payments $ 130,025 Less: imputed interest (27,983) Present value of operating lease liabilities $ 102,042 Operating lease liabilities, current $ 9,199 Operating lease liabilities, noncurrent 92,843 Total operating lease liabilities $ 102,042 The following table summarizes additional information related to operating leases as of March 31, 2023: March 31, December 31, 2022 Weighted-average remaining lease term 8.1 years 8.1 years Weighted-average discount rate 5.7 % 5.5 % Litigation The Company is regularly subject to lawsuits, claims, arbitration proceedings, administrative actions and other legal and regulatory proceedings involving intellectual property disputes, commercial disputes, competition and other matters, and the Company may become subject to additional types of lawsuits, claims, arbitration proceedings, administrative actions, government investigations and legal and regulatory proceedings in the future. Nanostring On May 6, 2021, the Company filed suit against Nanostring Technologies, Inc. ("Nanostring") in the U.S. District Court for the District of Delaware alleging that Nanostring's GeoMx Digital Spatial Profiler and associated instruments and reagents infringe U.S. Patent Nos. 10,472,669, 10,662,467, 10,961,566, 10,983,113 and 10,996,219 (the "GeoMx Action"). On May 19, 2021, the Company filed an amended complaint additionally alleging that the GeoMx products infringe U.S. Patent Nos. 11,001,878 and 11,008,607. On May 4, 2022, the Company filed an amended complaint in the GeoMx Action additionally alleging that the GeoMx products infringe U.S. Patent No. 11,293,917 and withdrawing the Company's claim of infringement of U.S. Patent No. 10,662,467. The Company seeks, among other relief, injunctive relief and unspecified damages (including attorneys’ fees) in relation to Nanostring's making, using, selling, offering to sell, exporting and/or importing in the United States the GeoMx Digital Spatial Profiler and associated instruments and reagents. Nanostring filed its answer to the GeoMx Action on May 18, 2022. Discovery is in progress. A Markman hearing was held on February 17, 2023 and the Court issued its claim construction order on February 28, 2023. Trial is scheduled for November 2023. On February 28, 2022, the Company filed a second suit against Nanostring in the U.S. District Court for the District of Delaware alleging that Nanostring's CosMx Spatial Molecular Imager and associated instruments, reagents and services infringe U.S. Patent Nos. 10,227,639 and 11,021,737 (the "CosMx Action"). On May 12, 2022, the Company filed an amended complaint in the CosMx Action additionally alleging that the CosMx products infringe U.S. Patent Nos. 11,293,051, 11,293,052 and 11,293,054. Nanostring filed its answer to the CosMx Action on May 26, 2022. On March 1, 2023, the Company filed a second amended complaint additionally alleging that the CosMx products infringe U.S. Patent No. 11,542,554. The Company seeks, among other relief, injunctive relief and unspecified damages (including attorneys’ fees) in relation to Nanostring's making, using, selling, offering to sell, exporting and/or importing in the United States the CosMx Spatial Molecular Imager and associated instruments, reagents, and services. Nanostring filed its answer to the second amended complaint on March 22, 2023. Discovery is in progress. A Markman hearing is scheduled for December 2023 and trial is scheduled for September 2024. On August 16, 2022, Nanostring filed a counterclaim in the CosMx Action alleging that the Company's Visium products infringe U.S. Patent No. 11,377,689. The Company filed its answer to Nanostring's counterclaim in the CosMx Action on August 30, 2022. On November 23, 2022, the Company moved to sever claims relating to NanoString’s assertion of U.S. Patent No. 11,377,689 and consolidate those claims with the patent case NanoString filed against the Company on October 20, 2022 (discussed below). On January 24, 2023, the Court granted the Company's motion. On April 27, 2023, Nanostring filed a motion in the CosMx Action to add antitrust, unfair competition, and contract counterclaims. Nanostring seeks, among other relief, injunctive relief (including that the Company grant Nanostring a license to the patents that the Company asserted against Nanostring in the CosMx Action) and unspecified damages (including attorney's fees). The Company believes Nanostring’s claims are meritless and intends to vigorously defend itself. On October 20, 2022, Nanostring filed a suit against the Company in the U.S. District Court for the District of Delaware alleging that the Company's Visium products infringe U.S. Patent No. 11,473,142, a continuation of U.S. Patent No. 11,377,689 (the "Nanostring Action"). Nanostring seeks, among other relief, injunctive relief and unspecified damages (including attorneys’ fees) in relation to the Company's making, using, selling, offering to sell, exporting and/or importing in the United States Visium products and associated instruments, reagents, and services. On January 24, 2023, the Court severed Nanostring’s claims with respect to U.S. Patent No. 11,377,689 from the CosMx Action and consolidated those claims with this action. Discovery is in progress. NanoString filed an amended complaint on January 27, 2023. The Company filed an answer to the NanoString Action on February 10, 2023. A Markman hearing is scheduled for December 2023 and trial is scheduled for December 2024. The Company believes Nanostring's claims in the Nanostring Action are meritless and intends to vigorously defend itself. On March 9, 2022, the Company filed suit in the Munich Regional Court in Germany alleging that Nanostring's CosMx Spatial Molecular Imager and associated instruments, reagents and services infringe EP Patent No. 2794928B1 (the "928 Patent") (the "Germany CosMx Action"). The Company seeks, among other relief, injunctive relief in relation to Nanostring's making, using, selling, offering to sell, exporting and/or importing in Germany the CosMx Spatial Molecular Imager and associated instruments and reagents. Nanostring filed its statement of defense to the Germany CosMx Action on August 26, 2022. A hearing on infringement was held on March 23, 2023 and a decision is expected around May 2023. On July 29, 2022, Nanostring filed a nullity action with the German Federal Patent Court challenging the validity of the 928 Patent. On February 10, 2023, the Federal Patent Court issued a preliminary opinion upholding the validity of certain claims of the 928 Patent directed to in situ analysis. A hearing on validity is scheduled before the Federal Patent Court in May 2024 and a decision is expected around the end of 2024. Vizgen In May 2022, the Company filed suit against Vizgen, Inc. ("Vizgen") in the U.S. District Court for the District of Delaware alleging that Vizgen’s MERSCOPE Platform and workflow and Vizgen’s Lab Services program, including associated instruments and reagents, infringe U.S. Patent Nos. 11,021,737, 11,293,051, 11,293,052, 11,293,054 and 11,299,767. The Company seeks, among other relief, injunctive relief and unspecified damages (including attorneys’ fees) in relation to Vizgen's making, using, selling, offering to sell, exporting and/or importing in the United States the MERSCOPE Platform and workflow and Vizgen's Lab Services program, including associated instruments and reagents. On July 25, 2022, Vizgen filed a motion to dismiss the Company's claims for willful and indirect infringement, which the Court denied on September 19, 2022. Discovery is in progress. A Markman hearing is scheduled for December 2023 and trial is scheduled for November 2024. On August 30, 2022, Vizgen filed its answer and counterclaims alleging that the Company's Xenium products infringes U.S. Patent No. 11,098,303. Vizgen seeks, among other relief, injunctive relief and unspecified damages (including attorneys’ fees) in relation to the Company's making, using, selling, offering to sell, exporting and/or importing in the United States Xenium products, including associated instruments and reagents. Vizgen also filed counterclaims alleging that the Company tortiously interfered with Vizgen's contractual and business relationship with Harvard and that the Company engaged in unfair practices under Massachusetts state law. On October 27, 2022, the Company filed a partial answer and motion to dismiss the infringement counterclaim and the tort counterclaims. On February 2, 2023, the Company's motion to dismiss was denied. On March 15, 2023, the Company filed an amended complaint additionally alleging that the MERSCOPE Platform and workflow and Vizgen’s Lab Services program infringe U.S. Patent No. 11,549,136 and withdrawing its claim of infringement of U.S. Patent No. 11,293,054. On April 17, 2023, Vizgen filed its answer adding antitrust, unfair competition, tort, and contract counterclaims. Vizgen seeks, among other relief, injunctive relief (including that the Company grant Vizgen a license to the patents that the Company asserted against Vizgen) and unspecified damages (including attorneys' fees). The Company believes Vizgen’s claims are meritless and intends to vigorously defend itself. Parse On August 24, 2022, the Company filed suit against Parse Biosciences, Inc. ("Parse") in the U.S. District Court for the District of Delaware alleging that Parse’s Evercode Whole Transcriptomics and ATAC-seq products infringe U.S. Patent Nos. 10,155,981, 10,697,013, 10,240,197, 10,150,995, 10,619,207, and 10,738,357. The Company seeks, among other relief, injunctive relief and unspecified damages (including attorneys’ fees) in relation to Parse's making, using, selling, offering to sell, exporting and/or importing in the United States the Evercode Whole Transcriptomics and ATAC-seq products. On October 17, 2022, Parse filed a motion to dismiss alleging that the asserted claims are directed to patent ineligible subject matter. The Court held a hearing on the motion to dismiss on November 22, 2022, and supplemental briefing was submitted on December 15, 2022. The Court has not yet ruled on the motion. Discovery is in progress. A Markman hearing is scheduled for February 2024 and trial is scheduled for December 2024. On April 20, 2023, Parse filed petitions for Inter Partes Review of U.S. Patent Nos. 10,155,981 and 10,150,995.

Capital Stock

Capital Stock	3 Months Ended
	Mar. 31, 2023
Equity [Abstract]
Capital Stock	Capital Stock As of March 31, 2023, the number of shares of Class A common stock and Class B common stock issued and outstanding were 98,106,087 and 18,067,255, respectively. The following table represents the number of shares of Class B common stock converted to shares of Class A common stock upon the election of the holders of such shares during the periods: Three Months Ended 2023 2022 Class B common stock converted to Class A common stock 600,000 200,000

Equity Incentive Plans

Equity Incentive Plans	3 Months Ended
	Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]
Equity Incentive Plans	Equity Incentive Plans Stock-based Compensation The Company recorded stock-based compensation expense in the condensed consolidated statement of operations for the periods presented as follows (in thousands): Three Months Ended 2023 2022 Cost of revenue $ 1,461 $ 1,014 Research and development 17,780 11,291 Selling, general and administrative 22,860 13,742 Total stock-based compensation expense $ 42,101 $ 26,047 Restricted Stock Units Restricted stock unit activity for the three months ended March 31, 2023 is as follows: Restricted Stock Weighted-Average Outstanding as of December 31, 2022 5,836,192 $ 52.21 Granted 584,720 45.72 Vested (397,222) 64.75 Cancelled (152,540) 59.81 Outstanding as of March 31, 2023 5,871,150 $ 50.51 Stock Options Stock option activity for the three months ended March 31, 2023 is as follows: Stock Options Weighted-Average Outstanding as of December 31, 2022 7,964,557 $ 37.10 Granted 272,904 50.10 Exercised (581,111) 4.13 Cancelled and forfeited (99,989) 85.63 Outstanding as of March 31, 2023 7,556,361 $ 39.46 Market-based Performance Stock Awards In March 2023, the Company granted 172,842 performance restricted stock unit awards (PSAs) under the 2019 Plan to certain members of management, which are subject to the achievement of certain escalating stock price thresholds established by the Company's Compensation Committee of the Board of Directors. The PSAs each vest in equal installments upon the achievement of escalating stock price thresholds of $72.14, $96.19 and $120.24 respectively, calculated based on the volume-weighted average price per share of the Company’s Class A common stock over the immediately trailing 20 trading day period for each respective threshold. The escalating stock price thresholds can be met any time prior to the fifth anniversary of the date of grant. The vesting of the PSAs can also be triggered upon certain change in control events and achievement of certain change in control price thresholds, or in the event of death or disability. The weighted-average grant date fair value of the PSAs was $43.13. Stock-based compensation expense recognized for these market-based awards was approximately $0.2 million for the three months ended March 31, 2023. The Company estimates the fair values of shares granted under the PSAs using a Monte Carlo simulation model with the following assumptions: Three Months Ended March 31, 2023 Expected volatility 71% Risk-free interest rate 3.7% Expected dividend —% In September 2022, the Company granted 709,025 PSAs including performance stock options and RSUs under the 2019 Plan to certain members of management, which are subject to the achievement of certain escalating stock price thresholds established by the Company's Compensation Committee of the Board of Directors. As of March 31, 2023, none of the escalating stock price thresholds had been met for any of the PSAs, resulting in no shares vesting or becoming exercisable. 2019 Employee Stock Purchase Plan A total of 3,486,671 shares of Class A common stock were reserved for issuance under the 2019 Employee Stock Purchase Plan ("ESPP"). The price at which Class A common stock is purchased under the ESPP is equal to 85% of the fair market value of the common stock on the first day of the offering period or purchase date, whichever is lower. During the three months ended March 31, 2023 and 2022, no shares of Class A common stock were issued under the ESPP. As of March 31, 2023, there were 3,108,600 shares available for issuance under the ESPP.

Net Loss Per Share

Net Loss Per Share	3 Months Ended
	Mar. 31, 2023
Earnings Per Share [Abstract]
Net Loss Per Share	Net Loss Per Share The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have had an anti-dilutive effect: Three Months Ended 2023 2022 Stock options to purchase common stock 7,556,361 8,419,444 Restricted stock units 5,871,150 1,610,391 Shares committed under ESPP 100,253 60,181 Shares subject to repurchase — 12,500 Total 13,527,764 10,102,516

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying condensed consolidated financial statements, which include the Company’s accounts and the accounts of its wholly-owned subsidiaries, are unaudited and have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). The condensed consolidated balance sheets at December 31, 2022 have been derived from the audited consolidated financial statements of the Company at that date. Certain information and footnote disclosures typically included in the Company’s audited consolidated financial statements have been condensed or omitted. The accompanying unaudited condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to state fairly the Company’s financial position, results of operations, comprehensive loss and cash flows for the periods presented, but are not necessarily indicative of the results of operations to be anticipated for any future annual or interim period. All intercompany transactions and balances have been eliminated. The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities. Actual results could differ from those estimates. The inputs into our judgments and estimates consider the economic implications of COVID-19 on our critical and significant accounting estimates.
Revenue Recognition	Revenue Recognition The Company generates revenue from sales of products and services, and its products consist of instruments and consumables. Revenue from product sales is recognized when control of the product is transferred, which is generally upon shipment to the customer. Instrument service agreements, which relate to extended warranties, are typically entered into for one-year terms, following the expiration of the standard one-year warranty period. Revenue for extended warranties is recognized ratably over the term of the extended warranty period as a stand ready performance obligation. Revenue is recorded net of discounts, distributor commissions and sales taxes collected on behalf of governmental authorities. Customers are invoiced generally upon shipment, or upon order for services, and payment is typically due within 45 days. Cash received from customers in advance of product shipment or providing services is recorded as a contract liability. The Company’s contracts with its customers generally do not include rights of return or a significant financing component. The Company regularly enters into contracts that include various combinations of products and services which are generally distinct and accounted for as separate performance obligations. The transaction price is allocated to each performance obligation in proportion to its standalone selling price. The Company determines standalone selling price using average selling
Net Loss Per Share	Net Loss Per Share Net loss per share is computed using the two-class method required for multiple classes of common stock and participating securities. The rights, including the liquidation and dividend rights and sharing of losses, of the Class A common stock and Class B common stock are identical, other than voting rights. As the liquidation and dividend rights and sharing of losses are identical, the undistributed earnings are allocated on a proportionate basis and the resulting net loss per share will, therefore, be the same for both Class A and Class B common stock on an individual or combined basis. Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period, adjusted for outstanding shares that are subject to repurchase. For the calculation of diluted net loss per share, basic net loss per share is adjusted by the effect of dilutive securities including awards under the Company’s equity compensation plans. Diluted net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding. For periods in which the Company reports net losses, diluted net loss per share is the same as basic net loss per share because potentially dilutive shares of common stock are not assumed to have been issued if their effect is anti-dilutive.

Other Financial Statement Inf_2

Other Financial Statement Information (Tables)	3 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Marketable Securities	Available-for-sale securities consisted of the following (in thousands): March 31, 2023 December 31, 2022 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Fair Value Measurement Cash equivalents: Money market funds $ 302,826 $ — $ — $ 302,826 $ 163,184 $ — $ — $ 163,184 Level 1 Marketable securities: Corporate debt securities 32,623 — (382) 32,241 153,794 4 (2,768) 151,030 Level 2 Government debt securities 49,632 — (828) 48,804 54,136 — (1,247) 52,889 Level 2 Asset-backed securities 4,999 — (74) 4,925 6,424 — (105) 6,319 Level 2 Total available-for-sale securities $ 390,080 $ — $ (1,284) $ 388,796 $ 377,538 $ 4 $ (4,120) $ 373,422
Debt Securities, Available-for-sale	The contractual maturities of marketable securities as of March 31, 2023 were as follows (in thousands): Fair Value Due in one year or less $ 66,133 Due after one year to five years 19,837 Total marketable securities $ 85,970
Schedule of Inventory	Inventory was comprised of the following (in thousands): March 31, December 31, Purchased materials $ 37,100 $ 34,497 Work in progress 20,530 24,650 Finished goods 24,677 22,482 Inventory $ 82,307 $ 81,629
Schedule of Accrued Compensation and Related Benefits	Accrued compensation and related benefits were comprised of the following as of the dates indicated (in thousands): March 31, December 31, Accrued payroll and related costs $ 4,298 $ 2,052 Accrued bonus 5,587 17,081 Accrued commissions 2,769 5,143 Accrued acquisition-related compensation — 5,470 Other 4,920 2,929 Accrued compensation and related benefits $ 17,574 $ 32,675
Schedule of Accrued Expense and Other Current Liabilities	Accrued expenses and other current liabilities were comprised of the following as of the dates indicated (in thousands): March 31, December 31, Accrued legal and related costs $ 5,639 $ 3,102 Accrued license fee — 6,231 Accrued royalties for licensed technologies 4,501 4,707 Accrued property and equipment 22,167 26,750 Accrued professional services 4,318 5,180 Product warranties 3,206 3,023 Taxes payable 2,297 4,079 Other 5,258 6,707 Accrued expenses and other current liabilities $ 47,386 $ 59,779
Schedule of Changes in the Reserve for Product Warranties	Changes in the reserve for product warranties were as follows for the periods indicated (in thousands): Three Months Ended 2023 2021 Beginning of period $ 3,023 $ 994 Amounts charged to cost of revenue 1,630 775 Repairs and replacements (1,447) (672) End of period $ 3,206 $ 1,097
Schedule of Revenue of Recognized in Contract Liabilities	The following revenue recognized for the periods were included in contract liabilities as of December 31, 2022 and December 31, 2021 (in thousands): Three Months Ended 2023 2022 Deferred revenue recognized $ 2,107 $ 1,604
Schedule of Revenue by Source	The following table represents revenue by source for the periods indicated (in thousands). Spatial products include the Company's Visium and Xenium products: Three Months Ended 2023 2022 Instruments Chromium $ 11,626 $ 14,326 Spatial¹ 7,550 103 Total instruments revenue 19,176 14,429 Consumables Chromium 101,096 91,279 Spatial 11,282 6,671 Total consumables revenue 112,378 97,950 Services 2,731 2,117 Total revenue $ 134,285 $ 114,496 1 The Spatial instruments revenue in the first quarter of 2022 related to revenue from the Visium Accessory Kit.
Schedule of Revenue by Geographic Location	The following table presents revenue by geography based on the location of the customer for the periods indicated (in thousands): Three Months Ended 2023 2022 Americas United States $ 76,281 $ 57,441 Americas (excluding United States) 2,515 2,246 Total Americas 78,796 59,687 Europe, Middle East and Africa 28,422 20,532 Asia-Pacific China¹ 14,031 21,782 Asia-Pacific (excluding China) 13,036 12,495 Total Asia-Pacific 27,067 34,277 Total Revenue $ 134,285 $ 114,496 1

Commitments and Contingencies (

Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Summary of Company's Operating Lease Liabilities	Future net lease payments related to the Company’s operating lease liabilities as of March 31, 2023 is as follows (in thousands): Operating Leases 2023 (excluding the three months ended March 31, 2023) $ 10,208 2024 16,435 2025 15,330 2026 16,101 2027 15,476 Thereafter 56,475 Total lease payments $ 130,025 Less: imputed interest (27,983) Present value of operating lease liabilities $ 102,042 Operating lease liabilities, current $ 9,199 Operating lease liabilities, noncurrent 92,843 Total operating lease liabilities $ 102,042
Summary of Additional Information Related to Operating Leases	The following table summarizes additional information related to operating leases as of March 31, 2023: March 31, December 31, 2022 Weighted-average remaining lease term 8.1 years 8.1 years Weighted-average discount rate 5.7 % 5.5 %

Capital Stock (Tables)

Capital Stock (Tables)	3 Months Ended
	Mar. 31, 2023
Equity [Abstract]
Schedule of Common Stock Issued and Outstanding	The following table represents the number of shares of Class B common stock converted to shares of Class A common stock upon the election of the holders of such shares during the periods: Three Months Ended 2023 2022 Class B common stock converted to Class A common stock 600,000 200,000

Equity Incentive Plans (Tables)

Equity Incentive Plans (Tables)	3 Months Ended
	Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]
Recorded Stock-based Compensation Expense in the Condensed Consolidated Statement of Operations	The Company recorded stock-based compensation expense in the condensed consolidated statement of operations for the periods presented as follows (in thousands): Three Months Ended 2023 2022 Cost of revenue $ 1,461 $ 1,014 Research and development 17,780 11,291 Selling, general and administrative 22,860 13,742 Total stock-based compensation expense $ 42,101 $ 26,047
Summary of RSU activity	Restricted stock unit activity for the three months ended March 31, 2023 is as follows: Restricted Stock Weighted-Average Outstanding as of December 31, 2022 5,836,192 $ 52.21 Granted 584,720 45.72 Vested (397,222) 64.75 Cancelled (152,540) 59.81 Outstanding as of March 31, 2023 5,871,150 $ 50.51
Summary of the Company's Stock Option Activity	Stock option activity for the three months ended March 31, 2023 is as follows: Stock Options Weighted-Average Outstanding as of December 31, 2022 7,964,557 $ 37.10 Granted 272,904 50.10 Exercised (581,111) 4.13 Cancelled and forfeited (99,989) 85.63 Outstanding as of March 31, 2023 7,556,361 $ 39.46
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions	The Company estimates the fair values of shares granted under the PSAs using a Monte Carlo simulation model with the following assumptions: Three Months Ended March 31, 2023 Expected volatility 71% Risk-free interest rate 3.7% Expected dividend —%

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	3 Months Ended
	Mar. 31, 2023
Earnings Per Share [Abstract]
Shares of Common Stock Equivalents Excluded from Computation of Diluted Net Loss Per Share	The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have had an anti-dilutive effect: Three Months Ended 2023 2022 Stock options to purchase common stock 7,556,361 8,419,444 Restricted stock units 5,871,150 1,610,391 Shares committed under ESPP 100,253 60,181 Shares subject to repurchase — 12,500 Total 13,527,764 10,102,516

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Revenue recognition, payment due period	45 days

Other Financial Statement Inf_3

Other Financial Statement Information - Available-for-Sale Securities (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Marketable Securities [Line Items]
Gross Unrealized Gains	$ 0	$ 4
Gross Unrealized Losses	(1,284)	(4,120)
Marketable securities, fair value	85,970
Total available-for-sale securities, amortized cost	390,080	377,538
Total available-for-sale securities, fair value	388,796	373,422
Money market funds | Level 1
Marketable Securities [Line Items]
Money market funds	302,826	163,184
Corporate debt securities | Level 2
Marketable Securities [Line Items]
Total marketable securities	32,623	153,794
Gross Unrealized Gains	0	4
Gross Unrealized Losses	(382)	(2,768)
Marketable securities, fair value	32,241	151,030
Government debt securities | Level 2
Marketable Securities [Line Items]
Total marketable securities	49,632	54,136
Gross Unrealized Gains	0	0
Gross Unrealized Losses	(828)	(1,247)
Marketable securities, fair value	48,804	52,889
Asset-backed securities | Level 2
Marketable Securities [Line Items]
Total marketable securities	4,999	6,424
Gross Unrealized Gains	0	0
Gross Unrealized Losses	(74)	(105)
Marketable securities, fair value	$ 4,925	$ 6,319

Other Financial Statement Inf_4

Other Financial Statement Information - Contractual Maturities of Marketable Securities (Details) $ in Thousands	Mar. 31, 2023 USD ($)
Fair Value
Due in one year or less	$ 66,133
Due after one year to five years	19,837
Total marketable securities	$ 85,970

Other Financial Statement Inf_5

Other Financial Statement Information - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Concentration Risk [Line Items]
Gross realized loss	$ 1,700	$ 0
Gross realized gains	0	$ 0
Transaction price allocated to remaining performance obligations	12,100
Deferred revenue	8,530		$ 7,867
Deferred revenue recognized	12,100		$ 11,000
Products and Services, Excluding Grant Revenue
Concentration Risk [Line Items]
Deferred revenue	$ 8,500

Other Financial Statement Inf_6

Other Financial Statement Information - Schedule of Inventory (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Purchased materials	$ 37,100	$ 34,497
Work in progress	20,530	24,650
Finished goods	24,677	22,482
Inventory	$ 82,307	$ 81,629

Other Financial Statement Inf_7

Other Financial Statement Information - Schedule of Accrued Compensation and Related Benefits (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accrued payroll and related costs	$ 4,298	$ 2,052
Accrued bonus	5,587	17,081
Accrued commissions	2,769	5,143
Accrued acquisition-related compensation	0	5,470
Other	4,920	2,929
Accrued compensation and related benefits	$ 17,574	$ 32,675

Other Financial Statement Inf_8

Other Financial Statement Information - Schedule of Accrued Expense And Other Current Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accrued legal and related costs	$ 5,639	$ 3,102
Accrued license fee	0	6,231
Accrued royalties for licensed technologies	4,501	4,707
Accrued property and equipment	22,167	26,750
Accrued professional services	4,318	5,180
Product warranties	3,206	3,023
Taxes payable	2,297	4,079
Other	5,258	6,707
Accrued expenses and other current liabilities	$ 47,386	$ 59,779

Other Financial Statement Inf_9

Other Financial Statement Information - Schedule of Changes in the Reserve for Product Warranties (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward]
Beginning of period	$ 3,023	$ 994
Amounts charged to cost of revenue	1,630	775
Repairs and replacements	(1,447)	(672)
End of period	$ 3,206	$ 1,097

Other Financial Statement In_10

Other Financial Statement Information - Revenue Recognition (Details)	Mar. 31, 2023
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-04-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Expected period of revenue recognition	12 months

Other Financial Statement In_11

Other Financial Statement Information - Schedule of Revenue of Recognized in Contract Liabilities (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Deferred revenue recognized	$ 2,107	$ 1,604

Other Financial Statement In_12

Other Financial Statement Information - Schedule of Revenue by Source (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Revenue from External Customer [Line Items]
Revenue	$ 134,285	$ 114,496
Instruments
Revenue from External Customer [Line Items]
Revenue	19,176	14,429
Chromium
Revenue from External Customer [Line Items]
Revenue	11,626	14,326
Spatial
Revenue from External Customer [Line Items]
Revenue	7,550	103
Consumables
Revenue from External Customer [Line Items]
Revenue	112,378	97,950
Chromium
Revenue from External Customer [Line Items]
Revenue	101,096	91,279
Spatial
Revenue from External Customer [Line Items]
Revenue	11,282	6,671
Services
Revenue from External Customer [Line Items]
Revenue	$ 2,731	$ 2,117

Other Financial Statement In_13

Other Financial Statement Information - Schedule of Revenue by Geographic Region (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 134,285	$ 114,496
Americas
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	78,796	59,687
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	76,281	57,441
Americas (excluding United States)
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	2,515	2,246
Europe, Middle East and Africa
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	28,422	20,532
Asia-Pacific
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	27,067	34,277
China
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	14,031	21,782
Asia-Pacific (excluding China)
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 13,036	$ 12,495

Commitments and Contingencies -

Commitments and Contingencies - Summary of Company's Operating Lease Liabilities (Detail) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Operating Leases
2023 (excluding the three months ended March 31, 2023)	$ 10,208
2024	16,435
2025	15,330
2026	16,101
2027	15,476
Thereafter	56,475
Total lease payments	130,025
Less: imputed interest	(27,983)
Present value of operating lease liabilities	102,042
Operating lease liabilities, current	9,199	$ 9,037
Operating lease liabilities, noncurrent	92,843	$ 86,139
Total operating lease liabilities	$ 102,042

Commitments and Contingencies_2

Commitments and Contingencies - Summary of Additional Information Related to Operating Leases (Detail)	Mar. 31, 2023	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Weighted-average remaining lease term	8 years 1 month 6 days	8 years 1 month 6 days
Weighted-average discount rate	5.70%	5.50%

Capital Stock - Additional Info

Capital Stock - Additional Information (Detail)	Mar. 31, 2023 shares
Common Class A
Class of Stock [Line Items]
Common stock shares issued (in shares)	98,106,087
Common stock shares outstanding (in shares)	98,106,087
Common Class B
Class of Stock [Line Items]
Common stock shares issued (in shares)	18,067,255
Common stock shares outstanding (in shares)	18,067,255

Capital Stock - Schedule of Com

Capital Stock - Schedule of Common Stock Issued and Outstanding (Details) - shares	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Shares Converted From Class B to Class A
Conversion of Stock [Line Items]
Conversion of stock, shares converted (in shares)	600,000	200,000

Equity Incentive Plans - Record

Equity Incentive Plans - Recorded Stock-Based Compensation Expense in the Condensed Consolidated Statement of Operations (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Share-based Payment Arrangement, Expensed [Line Items]
Stock-based compensation expense	$ 42,101	$ 26,047
Cost of revenue
Share-based Payment Arrangement, Expensed [Line Items]
Stock-based compensation expense	1,461	1,014
Research and development
Share-based Payment Arrangement, Expensed [Line Items]
Stock-based compensation expense	17,780	11,291
Selling, general and administrative
Share-based Payment Arrangement, Expensed [Line Items]
Stock-based compensation expense	$ 22,860	$ 13,742

Equity Incentive Plans - Summar

Equity Incentive Plans - Summary of RSU Activity (Detail)	3 Months Ended
	Mar. 31, 2023 $ / shares shares
Restricted Stock Units
Beginning balance (in shares) | shares	5,836,192
Granted (in shares) | shares	584,720
Vested (in shares) | shares	(397,222)
Cancelled (in shares) | shares	(152,540)
Ending balance (in shares) | shares	5,871,150
Weighted-Average Grant Date Fair Value (per share)
Beginning balance (in dollars per share) | $ / shares	$ 52.21
Granted (in dollars per share) | $ / shares	45.72
Vested (in dollars per share) | $ / shares	64.75
Cancelled (in dollars per share) | $ / shares	59.81
Ending balance (in dollars per share) | $ / shares	$ 50.51

Equity Incentive Plans - Summ_2

Equity Incentive Plans - Summary of Company's Stock Option Activity (Details)	3 Months Ended
	Mar. 31, 2023 $ / shares shares
Stock Options
Beginning balance (in shares) | shares	7,964,557
Granted (in shares) | shares	272,904
Exercised (in shares) | shares	(581,111)
Cancelled (in shares) | shares	(99,989)
Ending balance (in shares) | shares	7,556,361
Weighted-Average Exercise Price
Beginning balance (in dollars per share) | $ / shares	$ 37.10
Granted (in dollars per share) | $ / shares	50.10
Exercised (in dollars per share) | $ / shares	4.13
Cancelled (in dollars per share) | $ / shares	85.63
Ending balance (in dollars per share) | $ / shares	$ 39.46

Equity Incentive Plans - Additi

Equity Incentive Plans - Additional Information (Details) - USD ($)	1 Months Ended		3 Months Ended
	Mar. 31, 2023	Sep. 30, 2022	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock units, granted (in shares)			584,720
Weighted-average grant date fair value, granted (in dollars per share)			$ 45.72
Market-based Performance Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation arrangement by predetermined share price trading day			20 days
Weighted-average grant date fair value, granted (in dollars per share)			$ 43.13
Share based payment arrangement recognized			$ 200,000
Market-based Performance Awards | Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Proceeds from issuance of stock			72.14
Market-based Performance Awards | Tranche Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Proceeds from issuance of stock			96.19
Market-based Performance Awards | Tranche Three
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Proceeds from issuance of stock			$ 120.24
Performance Stock Options and Restricted stock Units | 2019 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock units, granted (in shares)	172,842	709,025
Employee Stock | 2019 Plan | Common Class A
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement percent			85%
Employee Stock | 2019 Employee Stock Purchase Plan | Common Class A
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for issuance (in shares)	3,108,600		3,108,600		3,486,671
Shares issued in period for previously outstanding awards (in shares)			0	0

Equity Incentive Plans - Fair V

Equity Incentive Plans - Fair Values Of Shares Under The Performance Stock Options (Details) - Performance Stock Awards	3 Months Ended
	Mar. 31, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	71%
Risk-free interest rate	3.70%
Expected dividend	0%

Net Loss Per Share - Shares of

Net Loss Per Share - Shares of Common Stock Equivalents Were Excluded From The Computation of Diluted Net Loss Per Share (Details) - shares	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	13,527,764	10,102,516
Stock options to purchase common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	7,556,361	8,419,444
Restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	5,871,150	1,610,391
Shares committed under ESPP
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	100,253	60,181
Shares subject to repurchase
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	0	12,500